Shire Vs Allergan Brings Exclusive Contracts Out Of The Shadows (Again)
Shire filed a lawsuit against Allergan, claiming that Allergan's exclusive contracting tactics for Restasis under Medicare Part D have blocked Xiidra from the market. It's the second recent suit highlighting exclusive contracts as anti-competitive.
You may also be interested in...
Pharmaceutical manufacturers have been hoping to fly under Washington, D.C.'s radar, but Allergan's attempt to shield Restasis from the IPR process using a controversial deal with a Native American tribe, has led to calls for an investigation.
Pfizer filed a lawsuit against J&J over its efforts to block sales of Pfizer's biosimilar Inflectra through exclusive contracting for Remicade. The suit claims J&J coerced payers by vowing to withhold all Remicade rebates if any Inflectra is reimbursed. J&J says Pfizer has failed to show the value of Inflectra.
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.